Rivernorth Capital Management’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.38M Hold
417,998
0.22% 130
2025
Q4
$4.33M Buy
417,998
+100,000
+31% +$1.03M 0.2% 146
2025
Q3
$3.27M Buy
+317,998
New +$3.26M 0.19% 145

Other funds holding DMAA

Rivernorth Capital Management's DMAA Position: Q1 2026 in Review

Rivernorth Capital Management held its Drugs Made In America Acquisition Corp (DMAA) position steady in Q1 2026 at 417,998 shares worth $4.38M. The position accounts for 0.22% of the portfolio, ranked #130.

Rivernorth Capital Management first reported a position in DMAA in Q3 2025 and has held it in 3 quarters since. 39 funds tracked by Wall St. Rank hold DMAA as of Q1 2026.

  • Rivernorth Capital Management held 417,998 shares of Drugs Made In America Acquisition Corp worth $4.38M as of Q1 2026.
  • Rivernorth Capital Management left its Drugs Made In America Acquisition Corp share count unchanged in Q1 2026.
  • Drugs Made In America Acquisition Corp made up 0.22% of Rivernorth Capital Management's portfolio in Q1 2026, its #130 holding.
  • Rivernorth Capital Management first reported a position in Drugs Made In America Acquisition Corp in Q3 2025 and has held it in 3 quarters since.
  • 39 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q1 2026.

Based on Rivernorth Capital Management's 13F filing for Q1 2026, filed 15 May 2026.